Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2014 - 2026)

Supernus Pharmaceuticals' (SUPN) quarterly Long-Term Deferred Tax came in at $30.8 million in Q1 2026, down 19.64% on a QoQ basis from $38.4 million in Q4 2025.

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2014 - 2026) Analysis & Trends

Supernus Pharmaceuticals (SUPN) has 9 years of Long-Term Deferred Tax data on file, last reported at $30.8 million in Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $30.8 million in Q1 2026; TTM through Mar 2026 was $30.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $38.4 million, changed N/A from the prior year.
  • Long-Term Deferred Tax for Q1 2026 stood at $30.8 million, down from $38.4 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for SUPN reached as high as $38.4 million in Q4 2025 and fell as low as $6.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Supernus Pharmaceuticals 2.72 Bn 2.34 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 30.82 Mn
Dec 31, 2025 38.35 Mn
Sep 30, 2025 8.79 Mn
Jun 30, 2025 6.18 Mn
Mar 31, 2020 34.07 Mn
Dec 31, 2019 32.06 Mn
Sep 30, 2019 27.95 Mn
Jun 30, 2019 25.98 Mn
Mar 31, 2019 27.97 Mn
Dec 31, 2018 29.68 Mn
Sep 30, 2018 31.37 Mn
Jun 30, 2018 25.53 Mn
Mar 31, 2018 26.25 Mn
Dec 31, 2017 20.84 Mn
Sep 30, 2017 28.81 Mn
Jun 30, 2017 11.89 Mn
Mar 31, 2017 11.33 Mn
Dec 31, 2016 41.73 Mn
Sep 30, 2016 42.26 Mn
Jun 30, 2016 16.39 Mn